Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2018-12-01
2020-03-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Study 27G Vitrectomy vs Larger Gauge Surgery
NCT04412525
20- Versus 23- Gauge System for Pars Plana Vitrectomy
NCT00411970
Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes
NCT02477605
The Safety Outcomes of 27 Gauge Vitrectomy for Posterior Segment Disease in High Myopia
NCT04360603
Long-shaft Vitrectomy Probe in Highly Myopic Eyes
NCT04902170
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
23G gauge needle vitrectomy surgery
Vitrectomy (23G gauge needle)
Vitrectomy surgery with 23G gauge needle technique
27G gauge needle vitrectomy surgery
Vitrectomy (27G gauge needle)
Vitrectomy surgery with 27G gauge needle technique
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitrectomy (23G gauge needle)
Vitrectomy surgery with 23G gauge needle technique
Vitrectomy (27G gauge needle)
Vitrectomy surgery with 27G gauge needle technique
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No prior vitrectomy surgery in the study eye
* No prior inclusion in this trial
* Scheduled for vitrectomy for floater removal or macular surgery
Exclusion Criteria
* Patients with proliferative diabetic retinopathy, endophthalmitis, uveitis and other eye disease that impacts the outcome of vitrectomy surgery Patients with HIV (Human Immune-deficiency Virus)
* Patients with history of drug abuse or alcoholism
* Patients participating in other drug or medical device clinical trials before screening for this trial
* Pregnancy, preparation for pregnancy during clinical trial, or breastfeeding
* Belief by the investigator that a patient's condition would hinder the clinical trial, such as a patient prone to mental stress, loss of control of mood, or depression
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prof. Dr. Peter Stalmans
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Peter Stalmans
Prof. Dr. Peter Stalmans
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Stalmans, MD Phd
Role: PRINCIPAL_INVESTIGATOR
UZ Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Leuven (UZ Leuven)
Leuven, Vl-Brabant, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S61408
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.